Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Blayne Welk, Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT02044510
First received: January 22, 2014
Last updated: May 28, 2014
Last verified: May 2014
  Purpose

The proposed study is a randomized, double blind placebo controlled multicenter study to determine the effectiveness of mirabegron in the treatment of neurogenic bladder dysfunction. Patients will be randomized into one of two trial arms: mirabegron 25mg for two weeks, with escalation to 50mg for the remaining 8 weeks, or matched placebo capsule for two weeks, with placebo escalation for the remaining 8 weeks. The study will treat a total of 72 patients (36 with placebo, 36 with mirabegron). The study hypothesis is that mirabegron will result in a statistically superior (increased) urodynamic bladder capacity.

The study duration is 12 weeks, with a 1-4 week run in period where no active or placebo treatment will be administered. The primary outcome is urodynamic bladder capacity. The study hypothesis is that treatment with mirabegron will increase urodynamic bladder capacity. Secondary outcome measures will be additional urodynamic parameters, urinary symptom scales, urinary quality of life indices, and voiding diary results.

Patients who are over 18 years of age with a diagnosis of multiple sclerosis or spinal cord injury will be eligible to participate. All eligible patients will have urodynamic studies performed within 4 weeks of trial enrollment, and at the end of study (week 9-10). Adverse events and study outcomes will be assessed at predefined study time points.


Condition Intervention Phase
Urinary Bladder, Neurogenic
Drug: Mirabegron
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients

Resource links provided by NLM:


Further study details as provided by Lawson Health Research Institute:

Primary Outcome Measures:
  • Bladder capacity [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    Urodynamic bladder capacity


Secondary Outcome Measures:
  • 3 day Voiding diary [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    The 3 day voiding diary is a simple patient maintained record of fluid intake, voided volume and incontinence episodes. This will be used to assess number of episodes of urgency incontinence, urinary frequency, longest time between voids, functional capacity, and mean voided volume

  • 24hr urinary pad weights [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    This will determine the amount of urinary incontinence that occurs over a 24hr period.

  • Quality of life (bladder specific) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    The Short Form-Qualiveen is a urinary specific quality of life measure developed and studied specifically for neurogenic bladder patients; validity, reliability and responsiveness have been established.

  • Quality of life (incontinence) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    The I-QOL is an incontinence specific quality of life tool that has been shown to be a valid, reliable and responsive measurement among patients with neurogenic bladder dysfunction

  • Patient reported outcome measure-NBSS [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    The Neurogenic bladder symptom score (NBSS) is a symptom specific measure of urinary symptoms developed for patients with neurogenic bladder dysfunction with demonstrated validity and reliability

  • Patient perception of bladder condition [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
    The patient perception of bladder condition is a commonly used measure in the assessment of oral medications for the treatment of overactive bladder symptoms

  • Adverse events [ Time Frame: 10 weeks ] [ Designated as safety issue: Yes ]
    Adverse events will be monitored passively. They will be actively monitored for hypertension, tachycardia, and urinary retention.

  • Secondary urodynamic characteristics: maximum detrusor pressure [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • Secondary urodynamic characteristics: Volume at maximum detrusor pressure [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • Secondary urodynamic characteristics: Bladder sensation [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • Secondary urodynamic characteristics: bladder compliance [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
  • Secondary urodynamic characteristics: Volume at first detrusor overactivity [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 72
Study Start Date: July 2014
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mirabegron
Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
Drug: Mirabegron
Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
Other Name: MYRBETRIQ
Placebo Comparator: Placebo
Inert placebo pill, matching active treatment pill.
Drug: Placebo
Matched placebo capsules to the intervention arm

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Diagnosis of traumatic or nontraumatic suprasacral SCI or multiple sclerosis (based on a neurologist assessment and/or the McDonald criteria)(28)
  • Age >18 years
  • Stable method of bladder management for >3months (either spontaneous or provoked voiding, or intermittent catheterization).
  • Bothersome urinary symptoms (urinary frequency, urgency, or urgency incontinence based on standard ICS definitions(29)) and completed 3 day voiding diary demonstrating at least 1 episode of non-stress based urinary incontinence over the 72hr period (this may be urgency based incontinence or unaware incontinence).
  • Patient is able to read and speak English

Exclusion criteria:

Based on Screening visit history:

  • Participation in another drug or device study in the 60 days prior to the screening visit.
  • Previous urologic surgery: Transurethral prostatectomy, bladder augmentation, sphincterotomy, bladder neck sling, artificial urinary sphincter, catheterizable channel, implantable electrostimulator/neuromodulator
  • Current use of suprapubic catheter/foley catheter
  • Unstable cardiac disease (uncontrolled hypertension, myocardial infarction, unstable angina, severe congestive heart failure (NYHA 3 or 4), ventricular arrhythmia (such as torsades de pointes), or stroke within the last 6 months)
  • Clinically significant abnormal ECG
  • The investigator believes the patient has an increased risk of QT prolongation (based on review of the screening ECG and patients concurrent medications)
  • History of significant renal dysfunction within 1 year, or serum creatinine >150umol/L at screening visit (visit 1).
  • History of significant liver disease within 1 year, or serum AST/ALT >2 times upper limit of normal, GGT >3 times upper limit of normal, total bilirubin >2 times upper limit of normal at screening visit (visit 1).
  • History of pelvic radiation
  • History of bladder cancer
  • History of a concurrent malignancy or cancer (except noninvasive skin cancer) within the last 5 years. Subjects with a history of cancer are considered eligible if the subject has undergone potentially curative therapy and the subject has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin).
  • Patient has a history of interstitial cystitis/pelvic pain syndrome
  • Patient has a history of acute or chronic urinary retention within the last 3 months, and is currently not using intermittent catheters
  • Patient has a history of a tachyarrhythmia
  • Patient has a history of glaucoma
  • Patient has a medical condition that may cause noncompliance with the study protocol
  • In the opinion of the Investigator the patient has a history of significant stress urinary incontinence
  • Patient has signs and symptoms of an active urinary tract infection (symptoms of dysuria, foul smelling urine, cloudy urine, increased spasticity, increased autonomic dysreflexia, self reported fever, increased incontinence, back/suprapubic pain).

    o Patient will submit urine for culture and sensitivity, undergo treatment, and will be eligible for rescreening after treatment.

  • Female patient who is pregnant or breastfeeding, or plans to become pregnant.
  • Male patient who is planning on fathering a child during the study or for 28 days after the last dose of study drug, or who is planning to donate sperm
  • Patient refuses to provide written consent
  • Patient will be unable or unwilling to complete the questionnaires and study visits
  • In the opinion of the study investigator, it is not in the patient's best interest to be enrolled in this study.

Based on medication and allergy review

  • Current use of anticholinergic medications for bladder dysfunction (oxybutynin, tolterodine, fesoterodine, solifenacin, darifenacin, trospium, hyoscine, oxybutynin gel or patch, atropine, benzatropine). If previously used, these medications must have been stopped for >2 weeks
  • Newly added bladder active medication (or dose change) within the last 2 months (Tamsulosin, Silodosin, Terazosin, Baclofen, Diazepam, amitriptyline, Finasteride, Dutasteride, DDAVP/desmopressin)
  • Use of flecainide, propafenone, donepezil, thioridazine, tramadol, aripiprazole, desipramine, imipramine, venlafaxine or digoxin
  • Intravesical onabotulinum toxin use within the last 1 year
  • Intravesical oxybutynin within the last 3 months
  • Patient has a previous history of treatment with mirabegron
  • Patient has a known allergy to mirabegron or a previous adverse reaction to a beta 3 agonist.

Based on physical exam

  • Patient has a postvoid residual > 250mL at study enrollment after repeated tested (1 attempt to re-void to ensure complete emptying of the bladder) and is not using intermittent catheters
  • Patient has a resting BP >180 mmHg systolic and/or >110 mmHg diastolic after 2 minutes of sitting quietly
  • Patient has a resting heart rate >100bpm after 2 minutes of sitting quietly
  • In the opinion of the study investigator, it is not in the patient's best interest to be enrolled in this study based on a clinically significant abnormality on physical exam.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02044510

Locations
Canada, Ontario
Western University
London, Ontario, Canada, N6A 4V2
University of Ottawa
Ottawa, Ontario, Canada, K1Y 4E9
Sponsors and Collaborators
Lawson Health Research Institute
Investigators
Principal Investigator: Blayne Welk, MD MSc Western University
  More Information

No publications provided

Responsible Party: Blayne Welk, Principal Investigator, Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT02044510     History of Changes
Other Study ID Numbers: SG193
Study First Received: January 22, 2014
Last Updated: May 28, 2014
Health Authority: Canada: Health Canada

Keywords provided by Lawson Health Research Institute:
Multiple Sclerosis
Spinal Cord Injuries
mirabegron
Urodynamics

Additional relevant MeSH terms:
Urinary Bladder, Neurogenic
Neurologic Manifestations
Nervous System Diseases
Urinary Bladder Diseases
Urologic Diseases
Signs and Symptoms
Mirabegron
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Urological Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on September 18, 2014